Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability, Safety, and Pharmacokinetics of Ondansetron Inhalation Powder
NCT07498751Phase 1Completed
- Start
- Mar 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LPI-1503 in postoperative nausea and vomiting (PONV) (7 arms). Primary endpoints: Number of Participants with Treatment-Emergent Adverse Events, Number of Participants with Serious Adverse Events and 12 more. Started Mar 2025; status: completed.
02
Drugs
LPI-1503
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT07498751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498751.